Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Pear Therapeutics, Inc. PEAR
$0.03
На 18:04, 12 мая 2023
+21 566.67%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
4088818.00000000
-
week52high
6.74
-
week52low
0.01
-
Revenue
12694000
-
P/E TTM
1
-
Beta
0.51990400
-
EPS
-0.36000000
-
Last Dividend
0.00000000
-
Next Earnings Date
15 мая 2023 г. в 10:59
Описание компании
Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal, oncology, and cardiovascular. Pear Therapeutics, Inc. was incorporated in 2013 and is based in Boston, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Chardan Capital | Buy | Buy | 12 авг 2022 г. |
| BTIG | Buy | Buy | 12 авг 2022 г. |
| Credit Suisse | Outperform | Outperform | 26 июл 2022 г. |
| BTIG | Buy | Buy | 24 июн 2022 г. |
| Citigroup | Buy | Buy | 17 мая 2022 г. |
| Citigroup | Buy | Buy | 16 ноя 2022 г. |
| Credit Suisse | Outperform | Outperform | 15 ноя 2022 г. |
| Chardan Capital | Buy | Buy | 15 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Jeffery Katherine | D | 8304 | 7096 | 20 янв 2023 г. |
| McCann Corey | D | 8210834 | 34731 | 20 янв 2023 г. |
| Maricich Yuri | D | 94333 | 12162 | 20 янв 2023 г. |
| GUIFFRE CHRISTOPHERD T | D | 29960 | 19540 | 20 янв 2023 г. |
| Snow Ellen | D | 23318 | 8027 | 20 янв 2023 г. |
| Brenner Erin K. | D | 43310 | 8690 | 20 янв 2023 г. |
| Strandberg Julia | D | 28612 | 12688 | 20 янв 2023 г. |
| O'Brien Ronan | D | 18638 | 12162 | 20 янв 2023 г. |
| Brenner Erin K. | D | 44667 | 22000 | 14 янв 2023 г. |
| Brenner Erin K. | A | 52000 | 22000 | 14 янв 2023 г. |
Новостная лента
Pear Therapeutics, Inc. (PEAR) Loses -17.39% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Zacks Investment Research
19 янв 2023 г. в 11:18
The heavy selling pressure might have exhausted for Pear Therapeutics, Inc. (PEAR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Pear Has Captive Markets With reSET, Guides $30 Million In 2023
Seeking Alpha
17 ноя 2022 г. в 11:04
Pear is focusing on its established substance abuse products now, putting development on a hold. Performance has been good into onboarding payors that have good coverage in markets where substance abuse is a problem.
Pear Therapeutics Inc. (PEAR) Q3 2022 Earnings Call Transcript
Seeking Alpha
14 ноя 2022 г. в 19:32
Pear Therapeutics Inc. (NASDAQ:PEAR ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Meara Murphy – Senior Director-Corporate Communications Corey McCann – President and Chief Executive Officer Ronan O'Brien – General Counsel Julia Strandberg – Chief Commercial Officer Yuri Maricich – Chief Medical Officer Chris Guiffre – Chief Financial Officer and Chief Operating Officer Erin Brenner – Chief Product Development Officer Conference Call Participants Eric Percher – Nephron Research Marie Thibault – BTIG Neena Bitritto-Garg – Citi Steve Braun – Cowen Keay Nakae – Chardan Rahul Rakhit – LifeSci Capital Operator Good afternoon, everyone. Welcome to the Pear Therapeutics Third Quarter 2022 Earnings Conference Call.
Pear Therapeutics Lays Off 9% Of Workforce, Guides For $15 Million Revenue
Seeking Alpha
18 авг 2022 г. в 06:00
Lots of payors are adding reSET to their covered benefit plans, and savings results far exceed prices of the products, usually leaving about 50% in surplus for the health system. Payor contract economics is making timing issues for revenue recognition, but run-rate revenue still indicates Pear is still annualising $12 million in revenue.
Pear Therapeutics, Inc. (PEAR) CEO Corey McCann on Q2 2022 Results - Earnings Call Transcript
Seeking Alpha
14 авг 2022 г. в 06:13
Pear Therapeutics, Inc. (NASDAQ:PEAR ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Meara Murphy - Senior Director of Corporate Communications Ronan O'Brien - General Counsel and Chief Compliance Officer Corey McCann - President and Chief Executive Officer Chris Guiffre - Chief Financial Officer and Chief Operating Officer Yuri Maricich - Chief Medical Officer Julia Strandberg - Chief Commercial Officer Conference Call Participants Judah Frommer - Credit Suisse Michael Cherny - Bank of America Neena Garg - Citi Eric Percher - Nephron Research Rahul Rakhit - LifeSci Capital Keay Nakae - Chardan Marie Thibault - BTIG Operator Good afternoon, everyone. Welcome to the Pear Therapeutics Second Quarter 2022 Earnings Conference Call.